JP2024012517A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024012517A5 JP2024012517A5 JP2023189168A JP2023189168A JP2024012517A5 JP 2024012517 A5 JP2024012517 A5 JP 2024012517A5 JP 2023189168 A JP2023189168 A JP 2023189168A JP 2023189168 A JP2023189168 A JP 2023189168A JP 2024012517 A5 JP2024012517 A5 JP 2024012517A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition
- rgdlatlrql
- mgs
- peg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025283311A JP2026062852A (ja) | 2017-07-10 | 2025-12-26 | がん治療用ペプチドサポリン複合体 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762530674P | 2017-07-10 | 2017-07-10 | |
| US62/530,674 | 2017-07-10 | ||
| PCT/US2018/041412 WO2019014199A1 (en) | 2017-07-10 | 2018-07-10 | PEPTIDE SAPORIN CONJUGATE FOR THE TREATMENT OF CANCER |
| JP2020501231A JP2020527556A (ja) | 2017-07-10 | 2018-07-10 | がん治療用ペプチドサポリン複合体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020501231A Division JP2020527556A (ja) | 2017-07-10 | 2018-07-10 | がん治療用ペプチドサポリン複合体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025283311A Division JP2026062852A (ja) | 2017-07-10 | 2025-12-26 | がん治療用ペプチドサポリン複合体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024012517A JP2024012517A (ja) | 2024-01-30 |
| JP2024012517A5 true JP2024012517A5 (https=) | 2024-05-02 |
Family
ID=65002607
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020501231A Pending JP2020527556A (ja) | 2017-07-10 | 2018-07-10 | がん治療用ペプチドサポリン複合体 |
| JP2023189168A Pending JP2024012517A (ja) | 2017-07-10 | 2023-11-06 | がん治療用ペプチドサポリン複合体 |
| JP2025283311A Pending JP2026062852A (ja) | 2017-07-10 | 2025-12-26 | がん治療用ペプチドサポリン複合体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020501231A Pending JP2020527556A (ja) | 2017-07-10 | 2018-07-10 | がん治療用ペプチドサポリン複合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025283311A Pending JP2026062852A (ja) | 2017-07-10 | 2025-12-26 | がん治療用ペプチドサポリン複合体 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11738089B2 (https=) |
| EP (1) | EP3652195A4 (https=) |
| JP (3) | JP2020527556A (https=) |
| CN (2) | CN118240025A (https=) |
| AU (2) | AU2018301651B2 (https=) |
| WO (1) | WO2019014199A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11965004B2 (en) | 2017-07-10 | 2024-04-23 | Sri International | Molecular guide system peptides and uses thereof |
| CN118240025A (zh) | 2017-07-10 | 2024-06-25 | 斯坦福国际研究院 | 用于治疗癌症的肽皂草素缀合物 |
| US20220380764A1 (en) * | 2019-10-01 | 2022-12-01 | Sri International | Molecular guide system peptides and uses thereof |
| US12516086B2 (en) | 2021-12-21 | 2026-01-06 | Sri International | Dual targeting for cell-specific delivery to the central nervous system |
| US20250215411A1 (en) * | 2022-03-09 | 2025-07-03 | Ospedale San Raffaele Srl | Fusion proteins and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7671010B2 (en) | 2002-08-30 | 2010-03-02 | The Board Of Regents Of The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
| WO2004003170A2 (en) | 2002-06-28 | 2004-01-08 | The Johns Hopkins University | Agents capable of inhibiting ras and uses thereof |
| JP2006521088A (ja) | 2002-11-15 | 2006-09-21 | メディカル リサーチ カウンシル | 抗活性化ｒａｓ抗体 |
| CA2524124C (en) | 2003-04-30 | 2014-03-25 | Uwe Zangemeister-Wittke | Methods for treating cancer using an immunotoxin |
| WO2005081898A2 (en) | 2004-02-20 | 2005-09-09 | The Trustees Of The University Of Pennsylvania | Binding peptidomimetics and uses of the same |
| EP1867661A1 (en) | 2006-06-12 | 2007-12-19 | Diatos | Compositions and methods for delivering anti-activated ras antibodies into cells |
| US20090110662A1 (en) | 2007-04-30 | 2009-04-30 | Intezyne Technologies, Inc. | Modification of biological targeting groups for the treatment of cancer |
| WO2009089186A2 (en) * | 2008-01-05 | 2009-07-16 | Sloan-Kettering Institute For Cancer Research | Peptide-conjugated oligonucleotide therapeutic and method of making and using same |
| EP2352522A4 (en) | 2008-11-06 | 2014-03-05 | Univ Washington | BISPECIFIC AUXILIARIES FOR INTRA-CELLULAR RELEASE |
| US8241623B1 (en) | 2009-02-09 | 2012-08-14 | David Bermudes | Protease sensitivity expression system |
| US8481678B2 (en) | 2009-03-30 | 2013-07-09 | E I Du Pont De Nemours And Company | Peptide-based tooth whitening reagents |
| CN101724073A (zh) | 2010-01-19 | 2010-06-09 | 成都军区昆明总医院 | 一种广谱抗ras基因表达蛋白的单克隆抗体及其制备方法 |
| US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
| US8362207B2 (en) | 2010-04-16 | 2013-01-29 | Wake Forest University Health Sciences | Multi-level specific targeting of cancer cells with IL-13 |
| WO2012040513A1 (en) * | 2010-09-22 | 2012-03-29 | The Board Of Regents Of The University Of Texas System | Compositions and methods for the delivery of beta lapachone |
| CA2816584A1 (en) | 2010-11-01 | 2012-05-10 | Peptimed, Inc. | Compositions of a peptide-based system for cell-specific targeting |
| US8515001B2 (en) | 2010-12-24 | 2013-08-20 | Lg Display Co., Ltd. | Shift register |
| EP2476441A1 (en) * | 2011-01-13 | 2012-07-18 | Universitat Autònoma De Barcelona | Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells |
| US20120283410A1 (en) | 2011-03-14 | 2012-11-08 | Intezyne Technologies, Incorporated | Attachment of biological targeting groups using metal free click chemistry |
| US9062312B2 (en) | 2011-06-21 | 2015-06-23 | Danisco Us Inc. | Fusion peptides comprising multi-functional peptidic solubility tags for efficient production, processing and surface applications |
| US9572898B2 (en) | 2013-09-09 | 2017-02-21 | Seton Hall University | Functionalized fluorine containing phthalocyanine molecules |
| GB201318954D0 (en) | 2013-10-28 | 2013-12-11 | Cupid Peptide Company Ltd | Cell transport |
| PT3137605T (pt) | 2014-05-01 | 2020-12-18 | Ionis Pharmaceuticals Inc | Composições e métodos para modulação da expressão de angiopoietina de tipo 3 |
| WO2016022597A1 (en) | 2014-08-04 | 2016-02-11 | Case Western Reserve University | Targeting peptides and methods of use |
| EP3226840B1 (en) | 2014-12-17 | 2020-07-29 | SRI International | Antigen delivery system |
| AU2017236431A1 (en) * | 2016-03-24 | 2018-09-27 | Bayer Pharma Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| US20180129937A1 (en) | 2016-11-04 | 2018-05-10 | Salesforce.Com, Inc. | Quasi-recurrent neural network |
| US20180157388A1 (en) | 2016-12-02 | 2018-06-07 | Google Inc. | Emotion expression in virtual environment |
| CA3047491A1 (en) * | 2016-12-21 | 2018-06-28 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| CN118240025A (zh) | 2017-07-10 | 2024-06-25 | 斯坦福国际研究院 | 用于治疗癌症的肽皂草素缀合物 |
| US11965004B2 (en) * | 2017-07-10 | 2024-04-23 | Sri International | Molecular guide system peptides and uses thereof |
-
2018
- 2018-07-10 CN CN202410388873.8A patent/CN118240025A/zh active Pending
- 2018-07-10 CN CN201880055897.4A patent/CN111417646B/zh active Active
- 2018-07-10 US US16/629,803 patent/US11738089B2/en active Active
- 2018-07-10 AU AU2018301651A patent/AU2018301651B2/en not_active Ceased
- 2018-07-10 WO PCT/US2018/041412 patent/WO2019014199A1/en not_active Ceased
- 2018-07-10 EP EP18831080.9A patent/EP3652195A4/en active Pending
- 2018-07-10 JP JP2020501231A patent/JP2020527556A/ja active Pending
-
2023
- 2023-07-14 US US18/352,791 patent/US12576157B2/en active Active
- 2023-08-17 AU AU2023216858A patent/AU2023216858A1/en not_active Abandoned
- 2023-11-06 JP JP2023189168A patent/JP2024012517A/ja active Pending
-
2025
- 2025-12-26 JP JP2025283311A patent/JP2026062852A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024012517A5 (https=) | ||
| ES2319827T3 (es) | Proteinas quimericas especificas del receptor il-13, y sus usos. | |
| EP2416805B1 (en) | Amatoxin antibody conjugates for the treatment of cancer | |
| ES2547348T3 (es) | Tratamiento de enfermedades hiperproliferativas con un superantígeno en combinación con un agente citostático | |
| US6518061B1 (en) | IL-13 receptor specific chimeric proteins and uses thereof | |
| JP2022105640A (ja) | 四級化チューブリシン化合物の複合体 | |
| Potala et al. | Targeted therapy of cancer using diphtheria toxin-derived immunotoxins | |
| IL184803A (en) | Purified antibodies against epha2, methods for their production, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating cancer | |
| KR20010102043A (ko) | 항-혈관형성 요법 및 면역요법을 병용한 종양 및 전이의치료 방법 | |
| JP2021505661A5 (https=) | ||
| Meyer-Losic et al. | Improved therapeutic efficacy of doxorubicin through conjugation with a novel peptide drug delivery technology (Vectocell) | |
| CN104781281A (zh) | 包含抗体部分、穿过血脑屏障的多肽和细胞毒素的结合物 | |
| McGonigle et al. | Neuropilin-1 drives tumor-specific uptake of chlorotoxin | |
| JP2020535171A (ja) | 去勢抵抗性前立腺癌 | |
| CN113941007B (zh) | 一种串联的双药物链接组装单元及其应用 | |
| JP2020527556A5 (https=) | ||
| PT94064B (pt) | Processo para a preparacao de novos conjugados de antraciclina que comportam um novo ligante e de composicoes farmaceuticas que os contem | |
| JP7608336B2 (ja) | 中枢神経系原発リンパ腫の併用治療 | |
| Engel et al. | Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins | |
| Li et al. | Immunotoxins and cancer therapy | |
| AU2002362210B2 (en) | Polypeptide, the conjugate thereof containing doxorubicine and a pharmaceutical composition based thereon | |
| Corti | Strategies for improving the anti-neoplastic activity of TNF by tumor targeting | |
| Chen et al. | Improved protein toxin delivery based on ATTEMPTS systems | |
| WO2010121125A1 (en) | Il-13 receptor binding peptides | |
| Shao et al. | Inhibition of human tumor xenograft growth in nude mice by a conjugate of monoclonal antibody LA22 to epidermal growth factor receptor with anti-tumor antibiotics mitomycin C |